Sirt result, page-72

Jcourse
it has nothing to do with ASX or in US. It is all about risk and reward for mid-cap pharma companies like SRX. If SRX is undervalued, big pharma will do a T/O vice versa.
A lot of holders in ASX might misinterpret the trail results, but certainly not me as I have personally overseas trials in Australia and in UK. The trails results will speak for itself. There is a reason why survival were used a a primary endpoint. People need to accept that not meeting primary endpoint in clinical trial is not something very unusual and perhaps also not the end of the world. Thus, a 12% dropped today is fair and reasonable. SRX still worth about $800-900mil which is why I was only sold 50% of my total holdings. the next 2 trails are extremely important.

DYOR